Prospective Measures of Outcome in Rapidly Progressive Dementia

Overview

About this study

This study will conduct assessment of patients with rapidly progressive dementia (RPD) to review clinical information and perform additional assessments to better understand the disease. Cognitive impairment and function will be assessed concurrent with clinical assessments using validated measures applied in the assessment and monitoring of patients with age-related neurodegenerative diseases. Clinical information will be combined with interval blood/serum, genetic (DNA, analyses of associated measures of transcription factors and proteins, with integration of induced pluripotent stem cell models), cerebrospinal fluid (CSF) and neuroimaging biomarkers when available. The ability of these novel measures to predict outcomes and clinical / pathological diagnoses will be prospectively considered. When available, clinical results from additional investigations (i.e., electroencephalograms, serum/CSF measures, additional imaging measures) obtained as a part of routine clinical assessment will also be reviewed and considered.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

  1. Patients age 18 years and older presenting with suspected rapidly progressing dementia (RPD), as defined by the following criteria:
    1. Loss of cognitive function that evolves hyperacutely (over days or weeks), subacutely (over months or 1-2 years) or more rapidly than expected with a known dementia syndrome.
    2. Diagnosis of RPD or rapidly-progressive encephalopathy by treating physician.
  1. Patient (or Collateral Source / Substitute Decision Maker) able to provide informed consent.  
  1. Admitted to Mayo Clinic Florida, or receiving follow-up through affiliated outpatient clinics.

 

Data from control patients will be obtained from existing sources (i.e., no new enrollment planned), including participants enrolled in research projects at collaborating institutions (e.g., the Memory and Aging Project at the Knight Alzheimer Disease Research Center; PI Dr. John C Morris).

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Gregory Day, M.D.

Open for enrollment

Contact information:

Anton Thomas

(904) 953-4096

Thomas.Anton@mayo.edu

More information

Publications

Publications are currently not available